Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Basilea Pharmaceutica AG, Allschwil
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics
Today 1:15 EST
From
Basilea Pharmaceutica AG, Allschwil
Via
GlobeNewswire
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States
December 16, 2024
From
Basilea Pharmaceutica AG, Allschwil
Via
GlobeNewswire
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year
October 10, 2024
From
Basilea Pharmaceutica AG, Allschwil
Via
GlobeNewswire
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
September 24, 2024
From
Basilea Pharmaceutica AG, Allschwil
Via
GlobeNewswire
Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding
September 19, 2024
From
Basilea Pharmaceutica AG, Allschwil
Via
GlobeNewswire
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea
September 06, 2024
From
Basilea Pharmaceutica AG, Allschwil
Via
GlobeNewswire
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea
August 27, 2024
From
Basilea Pharmaceutica AG, Allschwil
Via
GlobeNewswire
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
August 21, 2024
From
Basilea Pharmaceutica AG, Allschwil
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.